J Bone Metab.  2019 Feb;26(1):19-24. 10.11005/jbm.2019.26.1.19.

Clinical Application of Bone Turnover Markers in Osteoporosis in Korea

• Park SY
• Ahn SH
• Yoo JI
• Chung YJ
• Jeon YK
• Yoon BH
• Kim HY
• Lee SH
• Lee J
• Hong S

• KMID: 2440641
• DOI: http://doi.org/10.11005/jbm.2019.26.1.19

Abstract

Bone turnover markers (BTMs) have important role in the management of osteoporosis. Recently the clinical application of BTMs has achieved significant progress and measurement of BTMs give us better understanding of pathogenesis of osteoporosis. However, the use of BTMs is still insufficient in Korea. We summarized the available methods and standard interval of the BTMs in Korea. Also we reviewed published literatures on pre-analytical variability in the measurement of BTMs and provided recommendations for standardized sample handling and patient preparation for reducing those pre-analytical variabilities. The clinical application of BTMs in patients with chronic kidney disease who have a higher fracture risk than the general population is summarized.

Keyword

Biomarkers; Bone remodeling; Bone turnover markers; Chronic kidney disease; Osteoporosis

MeSH Terms

Biomarkers
Bone Remodeling*
Humans
Korea*
Osteoporosis*
Renal Insufficiency, Chronic
Biomarkers

Reference

1. Peck WA. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993; 94:646–650. PMID: 8506892.

2. Weinstein RS. True strength. J Bone Miner Res. 2000; 15:621–625. PMID: 10780853.

3. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom. 2007; 10:102–110. PMID: 17289532.

4. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010; 285:25103–25108. PMID: 20501658.

5. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011; 6:121–145. PMID: 20936937.

6. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000; 11(Suppl 6):S2–S17. PMID: 11193237.

7. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996; 11:1531–1538. PMID: 8889854.

8. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000; 15:1526–1536. PMID: 10934651.

9. Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int. 2000; 11:76–82. PMID: 10663362.

10. Nishizawa Y, Nakamura T, Ohta H, et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab. 2005; 23:97–104.

11. Morris HA, Eastell R, Jorgensen NR, et al. Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta. 2017; 467:34–41. PMID: 27374301.

12. Yoo JI, Park AJ, Lim YK, et al. Age-related reference intervals for total collagen-I-N-terminal propeptide in healthy Korean population. J Bone Metab. 2018; 25:235–241. PMID: 30574468.

13. Nishizawa Y, Ohta H, Miura M, et al. Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab. 2013; 31:1–15. PMID: 23143508.

14. Szulc P, Naylor K, Hoyle NR, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int. 2017; 28:2541–2556. PMID: 28631236.

15. Bauer D, Krege J, Lane N, et al. National bone health alliance bone turnover marker project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012; 23:2425–2433. PMID: 22797491.

16. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011; 22:391–420. PMID: 21184054.

17. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the serum CrossLaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem. 1998; 44:2290–2300. PMID: 9799756.

18. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001; 47:694–702. PMID: 11274020.

19. Morovat A, Catchpole A, Meurisse A, et al. IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children. Clin Chem Lab Med. 2013; 51:2009–2018. PMID: 24072575.

20. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002; 31:57–61. PMID: 12110413.

21. Redmond J, Fulford AJ, Jarjou L, et al. Diurnal rhythms of bone turnover markers in three ethnic groups. J Clin Endocrinol Metab. 2016; 101:3222–3230. PMID: 27294326.

22. Clowes JA, Hannon RA, Yap TS, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002; 30:886–890. PMID: 12052458.

23. Stokes FJ, Ivanov P, Bailey LM, et al. The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem. 2011; 57:138–140. PMID: 20974796.

24. Rosenquist C, Fledelius C, Christgau S, et al. Serum CrossLaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998; 44:2281–2289. PMID: 9799755.

25. Roche Diagnostics. Elecsys β-Crosslaps/serum (B-CTX in serum) immunoassay cobas package insert (V 14.1). Manheim, DE: Roche Diagnostics;2014.

26. Roche Diagnostics GmbH. Total PINP (2014) (total procollagen type I amino-terminal propeptide) immunoassay Cobas package insert (V11.0). Mannheim, DE: Roche Diagnostics GmbH;2014.

27. Gass ML, Kagan R, Kohles JD, et al. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause. 2008; 15:667–675. PMID: 18327152.

28. Bhattoa HP, Nagy E, More C, et al. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study. Osteoporos Int. 2013; 24:179–186. PMID: 22422303.

29. Pasco JA, Henry MJ, Kotowicz MA, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res. 2004; 19:752–758. PMID: 15068498.

30. Weiler R, Keen R, Wolman R. Changes in bone turnover markers during the close season in elite football (soccer) players. J Sci Med Sport. 2012; 15:255–258. PMID: 22056612.

31. Nitta K, Yajima A, Tsuchiya K. Management of osteoporosis in chronic kidney disease. Intern Med. 2017; 56:3271–3276. PMID: 29021477.

32. Isakova T, Nickolas TL, Denburg M, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017; 70:737–751. PMID: 28941764.

33. Chiang C. The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrology (Carlton). 2017; 22(Suppl 2):11–13.

34. Ueda M, Inaba M, Okuno S, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis. 2002; 40:802–809. PMID: 12324916.

35. Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant. 1996; 11:1065–1072. PMID: 8671970.

36. Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis. 2013; 61:847–848. PMID: 23357107.